1Elcioglu OC,Ozkok A,Akpinar TS,et al.Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment:case report and literature review.Int J Hematol,2012,96:370-375.
4Bougie DW,Wilker PR,Wuitschick ED,et al.Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GP Ⅱ b/Ⅲ a.Blood,2002,100:,2071-2076.
7Dasgupta H, Blankenship JC, Wood GC, et al. Thrombocytopenia complicating treatment with intravenous glycoprotein Ⅱ/Ⅲ a receptor inhibitors : a pooled analysis. Am Heart J ,2000,140 : 206-211.
8Huxtable LM, Tafreshi M J, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein Ⅱ b/Ⅲ a receptor antagonists. Am J Cardiol,2006,97:426-429.
9[3]Kaito K,Otsubo H.Platelet size deviation width,platelet large cell ratio,and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia[J].Br J Haematol,2005,128(5):698-702.
10Stanworth SJ,Dyer C,Choo L,et al.Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions:background,rationale,and design of a clinical trial(trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions[J].Trans Med Rev,2009,24(3):163-171.
10Bougie DW, Wilker PR, Wuitschick ED, et al. Acutethrombocytopenia after treatment with tirofiban or eptifibatideis associated with antibodies specific for ligand-occupiedGPIIb/IIIa[J]. Blood, 2002,100(6):2071-2076.
